OTCPK:DECN

Stock Analysis Report

Executive Summary

Decision Diagnostics Corp. develops smart phone based remote electronic medical record technologies.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.

Share Price & News

How has Decision Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-28.6%

DECN

-0.1%

US Healthcare Services

1.0%

US Market


1 Year Return

-9.6%

DECN

15.8%

US Healthcare Services

6.7%

US Market

Return vs Industry: DECN underperformed the US Healthcare Services industry which returned 15.8% over the past year.

Return vs Market: DECN underperformed the US Market which returned 6.7% over the past year.


Share holder returns

DECNIndustryMarket
7 Day-28.6%-0.1%1.0%
30 Day0.4%-0.9%-1.8%
90 Day-28.6%-7.5%-1.8%
1 Year-9.6%-9.6%16.0%15.8%9.1%6.7%
3 Year-78.7%-78.7%57.5%57.0%46.1%36.6%
5 Year-91.7%-91.7%52.5%51.4%66.9%48.6%

Price Volatility Vs. Market

How volatile is Decision Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Decision Diagnostics undervalued based on future cash flows and its price relative to the stock market?

1.54x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate DECN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate DECN's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: DECN is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: DECN is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate DECN's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: DECN is good value based on its PB Ratio (1.5x) compared to the US Healthcare Services industry average (3.5x).


Next Steps

Future Growth

How is Decision Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Decision Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of DECN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Decision Diagnostics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Decision Diagnostics performed over the past 5 years?

42.0%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: DECN is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare DECN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DECN is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: DECN has a negative Return on Equity (-71.3%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: DECN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: DECN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Decision Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: DECN's short term assets ($1.2M) do not cover its short term liabilities ($2.4M)

Long Term Liabilities: DECN's short term assets (1.2M) exceeds its long term liabilities (245.1K)


Debt to Equity History and Analysis

Debt Level: DECN's debt to equity ratio (43.8%) is considered high

Reducing Debt: DECN's debt to equity ratio has reduced from 452.9% to 43.8% over the past 5 years.


Balance Sheet

Inventory Level: DECN has a low level of unsold assets or inventory.

Debt Coverage by Assets: DECN's debt is covered by short term assets (assets are 1.091210x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DECN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DECN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year


Next Steps

Dividend

What is Decision Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate DECN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DECN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if DECN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DECN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DECN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Decision Diagnostics's salary, the management and board of directors tenure and is there insider trading?

13.3yrs

Average management tenure


CEO

Decision Diagnostics has no CEO, or we have no data on them.


Management Age and Tenure

13.3yrs

Average Tenure

Experienced Management: DECN's management team is seasoned and experienced (13.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Keith Berman (66yo)

    CFO, Secretary & Director

    • Tenure: 16.8yrs
    • Compensation: US$314.20k
  • Chris Knapp

    Consultant

    • Tenure: 13.3yrs
  • Mark Krakauer

    Head of Genstrip Private Label Sales Efforts

    • Tenure: 5.6yrs

Board Members

  • Keith Berman (66yo)

    CFO, Secretary & Director

    • Tenure: 16.8yrs
    • Compensation: US$314.20k

Company Information

Decision Diagnostics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Decision Diagnostics Corp.
  • Ticker: DECN
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$3.917m
  • Shares outstanding: 156.68m
  • Website: https://www.decisiondiagnostics.co

Number of Employees


Location

  • Decision Diagnostics Corp.
  • 2660 Townsgate Road
  • Suite 300
  • Westlake Village
  • California
  • 91361
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DECNOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2002

Biography

Decision Diagnostics Corp. develops smart phone based remote electronic medical record technologies. The company offers prescription drugs; home testing products for the chronically ill; fulfillment servic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:46
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)